HBK Sorce Advisory LLC Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

HBK Sorce Advisory LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 989 shares of the medical research company’s stock after acquiring an additional 97 shares during the quarter. HBK Sorce Advisory LLC’s holdings in IQVIA were worth $250,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. BKM Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $32,000. Dynamic Advisor Solutions LLC boosted its position in shares of IQVIA by 15.9% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 1,825 shares of the medical research company’s stock valued at $402,000 after purchasing an additional 251 shares during the period. Raymond James Trust N.A. boosted its position in shares of IQVIA by 5.6% in the 4th quarter. Raymond James Trust N.A. now owns 12,149 shares of the medical research company’s stock valued at $2,811,000 after purchasing an additional 647 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $429,000. Finally, Advisor Resource Council acquired a new stake in shares of IQVIA in the 4th quarter valued at about $229,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IQV. The Goldman Sachs Group began coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Barclays decreased their price objective on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. Truist Financial decreased their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Evercore ISI decreased their price objective on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $255.73.

IQVIA Stock Down 0.1 %

NYSE IQV traded down $0.28 on Friday, hitting $224.57. 1,066,649 shares of the stock traded hands, compared to its average volume of 1,065,908. The stock has a 50-day moving average of $219.73 and a 200 day moving average of $228.90. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market capitalization of $40.92 billion, a P/E ratio of 30.46, a price-to-earnings-growth ratio of 2.10 and a beta of 1.49. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.